Market Report -- In Play (IDRA) - MSN Money PDF Print
MSN MoneyIdera Pharma presents final data from Phase 2 clinical trial of IMO-2055 monotherapy in renal cell carcinoma; median overall survival was 23.5 months ...Idera Pharmaceuticals Presents Final Data from Phase 2 Clinical ... Business Wire (press release)Idera Pharmaceuticals presents final data from clinical trial ... Therapeutics Daily (press release) (registration)Idera Pharmaceuticals Presents Interim Data From Phase 1b Clinical

... read more

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.